Is Cohance Lifesciences Ltd (COHANCE) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Cohance Lifesciences Ltd is a good quality company .

Is Cohance Lifesciences Ltd (COHANCE) undervalued or overvalued?

The key valuation ratios of Cohance Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Cohance Lifesciences Ltd (COHANCE) share price return in the past 10 years?

Data is not available for this company

Is Cohance Lifesciences Ltd (COHANCE) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Cohance Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Cohance Lifesciences Ltd (COHANCE)?

Company share prices are keep on changing according to the market conditions. The current trading price of Cohance Lifesciences Ltd (COHANCE) on 17-Apr-2026 16:59:59 at 16:59 is 391.60.

What is the market cap of Cohance Lifesciences Ltd (COHANCE)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Cohance Lifesciences stood at Rs. 14981.33 Cr.

What is the P/E ratio of Cohance Lifesciences?

The latest standalone P/E ratio of Cohance Lifesciences as of 17-Apr-2026 is 62.82.

What is the P/B ratio of Cohance Lifesciences Ltd (COHANCE)?

The latest standalone P/B ratio of Cohance Lifesciences Ltd (COHANCE) as of 17-Apr-2026 is 3.36.

What is the 52-week high and low of Cohance Lifesciences Ltd (COHANCE)?

The 52-week high of Cohance Lifesciences Ltd (COHANCE) is Rs. 1246.85 and the 52-week low is Rs. 267.85.

What is the TTM revenue of Cohance Lifesciences Ltd (COHANCE)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Cohance Lifesciences is Rs. 1793.12 (Cr.).

Cohance Lifesciences Ltd (COHANCE) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Cohance Lifesciences Ltd (COHANCE)
Brand: Cohance Lifesciences

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0%	0%	0%	23.9%	50.2%	40.8%	45.9%	33.4%	21.2%	18.4%	-
Value Creation Index ⓘ	NA	NA	NA	0.8	2.7	2.0	2.4	1.5	0.6	0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	378	834	1,010	1,320	1,340	1,051	1,198	2,051
Sales YoY Gr.	-	NA	NA	NA	120.7%	21.1%	30.8%	1.5%	-21.6%	13.9%	-
Adj EPS ⓘ	0	0	0	0	12	13.9	15.3	15.1	10.3	10.2	5.3
YoY Gr.	-	NA	NA	NA	NA	15.9%	10.5%	-1.2%	-31.7%	-1.3%	-
BVPS (₹) ⓘ	0	0	0	0	33.2	46.4	60	68.2	80.5	66	99.8
Adj Net Profit ⓘ	0	0	0	111	305	353	390	385	263	260	202
Cash Flow from Ops. ⓘ	0	0	0	50.4	407	383	330	457	358	288	-
Debt/CF from Ops. ⓘ	0	0	0	1.6	0.5	0.4	0.3	0.2	0.1	0.3	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	7.5%	-3.2%	13.9%
Adj EPS ⓘ	NA	-3.2%	-12.7%	-1.3%
BVPSⓘ	NA	14.7%	3.2%	-18%
Share Price	-	-4.1%	-6%	-66.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	18.8	42.5	34.9	28.8	23.6	13.9	13.9	6.4
Op. Profit Mgn % ⓘ	46.1	46.2	43.9	44.1	42.8	38.6	31.3	19.6
Net Profit Mgn % ⓘ	29.4	36.6	35	29.6	28.8	25	21.4	9.8
Debt to Equity ⓘ	0.1	0.2	0.1	0.1	0	0	0.1	-
Working Cap Days ⓘ	0	196	175	172	195	213	160	121
Cash Conv. Cycle ⓘ	0	81	57	69	89	104	95	75

Recent Performance Summary

Sales growth is good in last 4 quarters at 11.01%

Return on Equity has declined versus last 3 years average to 6.40%

Sales growth has been subdued in last 3 years -3.20%

Net Profit has been subdued in last 3 years -12.67%

	Standalone	Consolidated
TTM EPS (₹)	6.2	5.3
TTM Sales (₹ Cr.)	1,793	2,051
BVPS (₹) ⓘ	116.5	99.8
Reserves (₹ Cr.) ⓘ	4,418	3,778
P/BV ⓘ	3.36	3.93
PE ⓘ	62.82	74.28

From the Market
52 Week Low / High (₹)	267.85 / 1246.85
All Time Low / High (₹)	87.05 / 1359.00
Market Cap (₹ Cr.)	14,981
Equity (₹ Cr.)	38.3
Face Value (₹)	1
Industry PE ⓘ	42.1

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	378	834	1,010	1,320	1,340	1,051	1,198
Operating Expenses ⓘ +	206	449	567	739	766	646	822
Manufacturing Costs	53	122	150	189	184	137	150
Material Costs	101	225	298	394	403	312	301
Employee Cost	30	65	76	100	118	135	250
Other Costs ⓘ	22	36	43	55	61	62	122
Operating Profit ⓘ	172	385	443	582	574	406	375
Operating Profit Margin (%)	45.4%	46.1%	43.9%	44.1%	42.8%	38.6%	31.3%
Other Income ⓘ +	1	18	14	92	46	62	59
Exceptional Items ⓘ	0	0	0	0	0	0	0
Interest ⓘ	3	23	12	9	13	7	12
Depreciation ⓘ	11	24	32	39	48	55	77
Profit Before Tax ⓘ	158	405	468	668	560	406	344
Tax ⓘ	49	88	105	214	148	105	79
Profit After Tax	109	317	362	454	411	300	265
PAT Margin (%)	28.9%	38.0%	35.9%	34.4%	30.7%	28.6%	22.1%
Adjusted EPS (₹)	0.0	12.5	14.2	17.8	16.2	11.8	10.5
Dividend Payout Ratio (%)	0%	20%	14%	28%	37%	0%	0%

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	578	845	1,181	1,527	1,735	2,049	1,680
Share Capital ⓘ	0	13	25	25	25	25	25
Reserves ⓘ	578	832	1,155	1,502	1,710	2,023	1,654
Debt +	83	185	141	96	69	39	76
Long Term Debt	0	91	36	28	5	0	6
Short Term Debt	83	94	106	67	65	39	70
Minority Interest	0	0	0	0	0	0	144
Trade Payables	54	71	83	106	70	42	80
Others Liabilities ⓘ	102	191	171	238	236	124	1,051
Total Liabilities ⓘ	816	1,292	1,576	1,967	2,110	2,254	3,031
Fixed Assets
Net Fixed Assets ⓘ +	271	357	441	534	663	670	1,713
Gross Block	347	457	570	694	876	929	2,046
Accumulated Depreciation	77	100	128	160	212	260	332
CWIP ⓘ	111	102	96	30	165	179	256
Investments ⓘ	7	338	542	598	536	904	337
Inventories	157	175	201	283	313	231	167
Trade Receivables	148	117	102	236	111	134	284
Cash Equivalents	13	14	10	47	68	51	89
Others Assets ⓘ	109	190	184	237	254	86	186
Total Assets ⓘ	816	1,292	1,576	1,967	2,110	2,254	3,031

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	50	407	383	330	457	385	288
PBT ⓘ	158	405	468	668	560	406	344
Adjustment ⓘ	14	35	36	41	37	17	60
Changes in Working Capital ⓘ	-88	54	-12	-194	6	72	-32
Tax Paid ⓘ	-33	-86	-109	-184	-146	-110	-83
Cash Flow From Investing Activity ⓘ +	-65	-413	-311	-136	-195	-362	-255
Capex	-57	-103	-111	-75	-286	-52	-156
Net Investments	-7	-325	-201	-300	84	-310	623
Others ⓘ	-2	15	-0	239	6	-0	-723
Cash Flow From Financing Activity ⓘ +	26	7	-76	-156	-242	-40	3
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	52	91	-55	-10	-24	-5	-2
Interest Paid ⓘ	-3	-17	-9	-6	-12	-7	-10
Dividend Paid ⓘ	-19	-64	-25	-102	-204	0	0
Others ⓘ	-4	-3	13	-39	-3	-28	16
Net Cash Flow ⓘ	11	1	-5	37	20	-18	36

PARTICULARS	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	18.92	44.58	35.78	33.52	25.21	15.87	14.2
ROCE (%)	23.87	50.21	40.76	45.92	33.41	21.22	18.44
Asset Turnover Ratio	0.46	0.79	0.7	0.75	0.66	0.48	0.45
PAT to CFO Conversion(x)	0.46	1.28	1.06	0.73	1.11	1.28	1.09
Working Capital Days
Receivable Days	142	58	40	47	47	42	64
Inventory Days	152	73	68	67	81	94	61
Payable Days	193	101	94	87	80	66	74

About Cohance Lifesciences Ltd

Headquartered in Hyderabad, Cohance Lifesciences is a global, innovation-driven CDMO platform specialising in high-value, end-to-end solutions across the full spectrum of a molecule’s lifecycle - from early-stage development to large-scale commercialisation - with a marquee Customer Base across Pharmaceuticals and Specialty Chemicals.

With a focus on agility, innovation and global scalability, Cohance Lifesciences is reshaping the landscape of pharmaceutical manufacturing and development. The company collaborates with its customers to enhance their molecules and products, enabling them to deliver innovative solutions to their patients and consumers.

Business area of the company

The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.

Business verticals of the company

Pharma CDMO
Specialty Chemicals
API+

Achievements

Achieved B-rating 2024 disclosure both in Climate Change & Water Security.

Social Accountability SA8000.

Silver in Ecovadis Sustainability Assessment.

Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner- 2025.

British Safety Council’s International Safety Awards (ISA) 2025.

All facilities are certified with ISO 14001, ISO 45001.

Milestones

2020: The foundation was laid with the inclusion of RA Chem Pharma, known for its strong footprint in APIs, intermediates, and finished dosage formulations, setting the tone for a platform focused on quality and scientific depth.
2021: With the addition of ZCL Chemicals, the platform expanded its capability in complex intermediates, enhancing its ability to serve global pharmaceutical innovators.
2022: The journey progressed with Avra, bringing expertise in high-complexity chemistry and ADC payloads – positioning the platform to support next-generation therapeutics.
2023: Suven Pharmaceuticals merges with Cohance - Suven Pharmaceuticals, with its rich heritage in CRAMS and custom synthesis, joined hands with the growing platform. This marked a pivotal point where the vision of Cohance – a differentiated, technology-led CDMO platform – began to take shape.
2024: Expanding into next-gen therapeutic platforms - While the Cohance–Suven integration was underway, the platform advanced further with Sapala Organics (bringing oligonucleotide capabilities) and NJ Bio (offering end-to-end integrated ADC services), broadening scientific reach in novel modalities.
2025: Cohance Lifesciences announced a strategic investment of $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Cohance Lifesciences Ltd (COHANCE) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Cohance Lifesciences Share Price